



ASX Release

14 March 2017

**ZELDA THERAPEUTICS LIMITED
ACN 103 782 378**

Level 45
108 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com

Contacts

Corporate

Mr Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Directors

Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

ASX Code:

ZLD

Shares: 669,127,649

Options: 40,000,000

Closure of Unmarketable Parcel Share Sale Facility

Zelda Therapeutics Ltd (ASX: ZLD, Zelda Therapeutics or the Company) is pleased to announce that it closed the share sale facility for holders of Unmarketable Parcels of shares in the Company (**Facility**) on 7 March 2017.

The Company provided the Facility to holders of Unmarketable Parcels to sell their shares without incurring any brokerage or handling costs that could otherwise make a sale of their shares uneconomic or difficult.

As at market close on 16 January 2017 (**Record Date**), there were 1,936,134 ordinary shares, held by 891 shareholders that had a market value of less than A\$500 (**Unmarketable Parcels**). The final number of shares eligible to be sold under the Facility was 1,090,520 ordinary shares from 744 shareholders which represents approximately 48% of the 1,545 shareholders presently holding shares in the Company.

The shares were sold on market by CPS Capital Pty Ltd at a price of \$0.0623 per share. Payment will be remitted to shareholders as soon as practicable.

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (*Aunt Zelda's*) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has embarked on a programme of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer. It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.